Filing Details
- Accession Number:
- 0001203311-21-000010
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-02-05 20:00:40
- Reporting Period:
- 2021-02-04
- Accepted Time:
- 2021-02-05 20:00:40
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1060736 | Seagen Inc. | SGEN | Biological Products, (No Disgnostic Substances) (2836) | 911874389 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1167496 | B Clay Siegall | 21823 30Th Drive Se Bothell WA 98021 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-02-04 | 989 | $15.46 | 716,198 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-02-04 | 989 | $163.09 | 715,209 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2021-02-04 | 2,063 | $15.46 | 717,272 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-02-04 | 2,063 | $164.17 | 715,209 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2021-02-04 | 11,497 | $15.46 | 726,706 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-02-04 | 11,497 | $165.10 | 715,209 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2021-02-04 | 9,195 | $15.46 | 724,404 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-02-04 | 9,195 | $165.99 | 715,209 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2021-02-04 | 5,609 | $15.46 | 720,818 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-02-04 | 5,609 | $166.82 | 715,209 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2021-02-04 | 989 | $0.00 | 989 | $15.46 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2021-02-04 | 2,063 | $0.00 | 2,063 | $15.46 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2021-02-04 | 11,497 | $0.00 | 11,497 | $15.46 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2021-02-04 | 9,195 | $0.00 | 9,195 | $15.46 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2021-02-04 | 5,609 | $0.00 | 5,609 | $15.46 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 204,482 | 2021-08-24 | No | 4 | M | Direct | |
| 202,419 | 2021-08-24 | No | 4 | M | Direct | |
| 190,922 | 2021-08-24 | No | 4 | M | Direct | |
| 181,727 | 2021-08-24 | No | 4 | M | Direct | |
| 176,118 | 2021-08-24 | No | 4 | M | Direct |
Footnotes
- Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $162.43 to $163.42. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $163.47 to $164.45. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $164.48 to $165.44. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $165.48 to $166.47. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $166.49 to $167.23. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Options vested at a rate of 25% on 8/24/12 and monthly thereafter until all the options were fully vested on 8/24/15.
Billionaire Hedge Funds
